

[Department of Medicine Faculty Papers](https://jdc.jefferson.edu/medfp) **Department of Medicine**

6-1-2014

Understanding the power of perinatal events and metabolic status in childhood.

Bonita Falkner Department of Medicine and Pediatrics, Thomas Jefferson University

Julie Ingelfinger Pediatric Nephrology Unit, MassGeneral Hospital for Children at Massachusetts General for Children

Follow this and additional works at: [https://jdc.jefferson.edu/medfp](https://jdc.jefferson.edu/medfp?utm_source=jdc.jefferson.edu%2Fmedfp%2F120&utm_medium=PDF&utm_campaign=PDFCoverPages)

C Part of the [Pediatrics Commons](https://network.bepress.com/hgg/discipline/700?utm_source=jdc.jefferson.edu%2Fmedfp%2F120&utm_medium=PDF&utm_campaign=PDFCoverPages)

Let us know how access to this document benefits you

Recommended Citation

Falkner, Bonita and Ingelfinger, Julie, "Understanding the power of perinatal events and metabolic status in childhood." (2014). Department of Medicine Faculty Papers. Paper 120. https://jdc.jefferson.edu/medfp/120

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](http://www.jefferson.edu/university/teaching-learning.html/). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Understanding the Power of Perinatal Events and Metabolic Status in Childhood

Bonita Falkner, Julie Ingelfinger

[See related article, p 1326–1332](http://hyper.ahajournals.org/content/63/6/1326.full.pdf+html)

ver the past 25 years, the concept that perinatal events influence an individual's later health and susceptibility to disease has gained traction. After original observations by Barker et al,¹ epidemiological studies have identified a link between markers such as lower birth weight and placental weight with later cardiovascular, metabolic, and other diseases. The theory of fetal programming in response to the intrauterine environment has been supported by a body of elegant experimental investigations in animals. However, findings from clinical investigations in humans have not always been consistent, and other factors such as weight gain trajectories and various environmental exposures, such as diet, stress, and lifestyle behaviors, also influence later health. Moreover, prospective studies in humans that begin in the neonatal or even perinatal period are limited. Ethical limitations in the conduct of clinical research in newborn infants and young children are obvious, and creative approaches are needed to prospectively investigate the birth weight hypothesis. In this issue of *Hypertension*, Lurbe et al² report on a study that provides new insights on childhood origins of chronic disease.

The authors enrolled a sample of healthy newborn infants. All enrolled infants were born at term after uncomplicated pregnancies. The investigators stratified infants according to birth weight (small [SGA], appropriate [AGA], or large for gestational age [LGA]). Blood pressure (BP) was measured at 2 days of age. The infants were then re-examined at 6 months, 2 years, and 5 years. At each study visit, BP and growth parameters were obtained. At age 5 years, a blood sample was obtained for measurement of metabolic parameters.

Despite the relatively small sample size $(n=139)$ of the study, the results are very interesting. At birth, birth weight and BP are positively related. Each birth weight group gained similar amount of weight in each examination interval; the SGA infants remained the smallest and the LGA infants remained the largest at each subsequent examination. Weight gain within the first 6 months of life was similar in each birth

Correspondence to Bonita Falkner, MD, Department of Medicine and Pediatrics, Thomas Jefferson University, 833 Chestnut St, Suite 700, Philadelphia, PA 19107. E-mail bonita.falkner@jefferson.edu

(*Hypertension***. 2014;63:1166-1167.)**

© 2014 American Heart Association, Inc.

Hypertension **is available at http://hyper.ahajournals.org DOI: 10.1161/HYPERTENSIONAHA.114.03290**

weight group and was not related to BP or subsequent metabolic parameters. After 6 months, both current weight and weight gain were significantly and positively associated with birth weight; birth weight was not significantly associated with the BP level. Most interesting were the metabolic findings. As depicted by the authors in Figure 1, fasting insulin levels are higher in SGA infants who became heavy at age 5 years compared with AGA and LGA infants who become heavy at age 5 years. Most striking are the homeostatic model assessment index estimates of insulin resistance. As shown in the figure, SGA infants are insulin-resistant relative to AGA and LGA infants, regardless of their weight status at age 5 years. These findings, in a sample of healthy infants, indicate that one or a combination of factors related to lower birth weight set the stage for relative insulin resistance that is enduring and seems not to be driven only by excess weight gain.

Earlier epidemiological studies reported a significant inverse relationship between birth weight and subsequent BP, with hypertension considered to be a major mediating link between low birth weight and subsequent cardiovascular disease. Data in the current report by Lurbe et $al²$ suggest that metabolic variation may be a seminal mediating link as well. Regardless of weight gain, by age 5 years the SGA group was insulinresistant with lower high-density lipoprotein-cholesterol and higher uric acid levels, compared with the other birth weight groups. Together, these relative metabolic differences suggest that features of the metabolic syndrome are present early, with the risk that high BP could possibly evolve as a consequence of later adiposity.

Based on epidemiological associations between greater body weight at 1 year of age and lower risk of later cardiovascular disease,³ nutritional augmentation to promote growth was considered beneficial for SGA infants. Subsequent studies to test this idea reported that overnutrition in early infancy was associated with later metabolic abnormalities^{4,5} and suggested that overnutrition with accelerated weight gain in the first months of life contributed to adverse metabolic changes. However, metabolic assessments in these studies were obtained in later childhood⁴ or adolescence.⁵ Contrary to these reports, Lurbe et al² found that weight gain within the first 6 months had no effect on metabolic variations measured at age 5 years in SGA infants. Based on a systematic review of published evidence on the association of birth weight with type 2 diabetes mellitus in adults, Whincup et al⁶ reported that in most populations birth weight was inversely related to type 2 diabetes mellitus. The report by Lurbe et al² in this issue adds novel findings on the low birth weight pathway to chronic disease with data demonstrating relative insulin resistance at age 5 years in SGA infants. Recently, in a cross-sectional study

The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.

From the Department of Medicine and Pediatrics, Thomas Jefferson University, Philadelphia, PA (B.F.); and Pediatric Nephrology Unit, MassGeneral Hospital for Children at Massachusetts General for Children, Boston, MA (J.I.).

in Brazil, Crispim et al⁷ reported findings similar to those of Lurbe et al, 2 but their study was not prospective.

Other issues of interest in the authors' study cohort include the rather high rates of obesity at age 5 years. Fifty percent of LGA newborns were obese at age 5 years, although this sample was limited to 20 children. The obesity prevalence may reflect the current childhood obesity epidemic but could also augment some of the metabolic parameters that were studied. Absent are data on maternal and perinatal parameters including maternal weight, diet, social economic status, and other exposures, as well as maternal weight postpartum. Such information would permit multivariable analysis that might help control for additional factors that may have influenced the results.

In all, the results of the study by Lurbe et $al²$ suggest that metabolic status in 5-year-old children born at term may be influenced or programmed by perinatal events. A variety of potential mechanisms have been considered to explain the developmental origins of health and disease, such as changes in the microarchitecture of various organs, changes in transporters or hormonal levels, and changes that involve epigenetic alterations. Epigenetic modification is a term that indicates modifications in DNA without changes in the DNA sequence per se. These changes may occur via methylation of cytosine in CpG dinucleotides, by phosphorylation, and ADP ribosylation. Other possible changes include the ubiquitination of histones and acetylation. Additionally, the function and conformation of chromatin can be altered by noncoding RNAs. Epigenetic modification may alter the way by which transcription activators and repressors bind to the DNA. The type of epigenetic change may influence the effects—although histone modifications of DNA have relatively short-term effects, DNA methylation may lead to longer-term changes.

There are evolving theories as to how epigenetic changes might influence programming of cardiovascular disease. Although epigenetic changes may be reversible, some epigenetic modifications may be inherited. In other words, epigenetic changes occur as part of the life cycle, but they also occur in response to stress. Thus, the concept that a stressful perinatal environment would potentially lead to epigenetic alterations in the stressed fetus or newborn is attractive. Some of these potential changes will affect the individual in later life, and some might be passed on to future generations. Most epigenetic data with respect to perinatal programming are experimental,⁸ but some human data support the concept that intrauterine stress leads to epigenetic change. For example, changes in the patterns of DNA methylation of insulin-like growth factor 2 (*IGF2DMR*) have been noted in persons exposed to famine conditions in utero.⁹ Indeed, the IGF2 and H19 loci have been thought to influence birth weight and growth, though results are conflicting.¹⁰ Bouwland-Both et $al¹¹$ recently examined a

prospective birth cohort of SGA children in The Netherlands and compared them to children who were AGA at term. The authors extracted DNA from umbilical cord white blood cells, examined DNA methylation, and observed that decreased DNA methylation of *IGF2DMR* was present among SGA children.

Further epigenetic studies may be helpful to our interpretation of prospective studies such as Lurbe et al's.2 One hopes that banking of cord blood samples may allow comparisons of physiological results to both genetic and epigenetic studies. To understand the phenomenon of perinatal programming, it will be necessary to take careful phenotypic observations such as those of the current study and pair them with molecular mechanisms. The molecular ability to do so is increasingly available and has the potential to deepen our understanding on fetal origins of chronic diseases such as hypertension and diabetes mellitus.

Disclosures

None.

References

- 1. Barker DJ, Osmond C, Golding J, Kuh D, Wadsworth ME. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. *BMJ*. 1989;298:564–567.
- 2. Lurbe E, Garcia-Vicent C, Torro MI, Aguilar F, Redon J. Associations of birth weight and postnatal weight gain with cardiometabolic risk parameters at five years of age. *Hypertension*. 2014;63:1326–1332.
- 3. Eriksson JG, Forsén T, Tuomilehto J, Osmond C, Barker DJ. Early growth and coronary heart disease in later life: longitudinal study. *BMJ*. 2001;322:949–953.
- 4. Singhal A, Cole TJ, Fewtrell M, Kennedy K, Stephenson T, Elias-Jones A, Lucas A. Promotion of faster weight gain in infants born small for gestational age: is there an adverse effect on later blood pressure? *Circulation*. 2007;115:213–220.
- 5. Fabricius-Bjerre SJR, Faerch K, Larsen T, Molgaard C, Michaelsen KF, Vaag A, Greisen G. Impact of birth weight and early infant weight gain on insulin resistance and associated cardiovascular risk factors in adolescence. *PLoS One*. 2011;6:e20595.
- 6. Whincup PH, Kaye SJ, Owen CG, et al. Birth weight and risk of type 2 diabetes: a systematic review. *JAMA*. 2008;300:2886–2897.
- 7. Crispim PAA, Peixoto MRG, Jardim PCBV. Risk factors associated with high blood pressure in two to five year old children. *Arq Bras Cardiol*. 2014;102:39–46.
- 8. Bogdarina I, Haase A, Langley-Evans S, Clark AJ. Glucocorticoid effects on the programming of AT1b angiotensin receptor gene methylation and expression in the rat. *PLoS One*. 2010;5:e9237.
- 9. Heijmans BT, Tobi EW, Stein AD, Putter H, Blauw GJ, Susser ES, Slagboom PE, Lumey LH. Persistent epigenetic differences associated with prenatal exposure to famine in humans. *Proc Natl Acad Sci U S A*. 2008;105:17046–17049.
- 10. Adkins RM, Somes G, Morrison JC, Hill JB, Watson EM, Magann EF, Krushkal J. Association of birth weight with polymorphisms in the IGF2, H19, and IGF2R genes. *Pediatr Res*. 2010;68:429–434.
- 11. Bouwland-Both MI, van Mil NH, Stolk L, Eilers PH, Verbiest MM, Heijmans BT, Tiemeier H, Hofman A, Steegers EA, Jaddoe VW, Steegers-Theunissen RP. DNA methylation of IGF2DMR and H19 is associated with fetal and infant growth: the Generation R Study. *PLoS One*. 2013;8:e81731.

Bonita Falkner and Julie Ingelfinger **Understanding the Power of Perinatal Events and Metabolic Status in Childhood**

Print ISSN: 0194-911X. Online ISSN: 1524-4563 Copyright © 2014 American Heart Association, Inc. All rights reserved. *Hypertension* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 doi: 10.1161/HYPERTENSIONAHA.114.03290 *Hypertension.* 2014;63:1166-1167; originally published online March 31, 2014;

<http://hyper.ahajournals.org/content/63/6/1166> World Wide Web at: The online version of this article, along with updated information and services, is located on the

this process is available in the [Permissions and Rights Question and Answer d](http://www.ahajournals.org/site/rights/)ocument. click Request Permissions in the middle column of the Web page under Services. Further information about Office. Once the online version of the published article for which permission is being requested is located, in *Hypertension* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial **Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published

<http://www.lww.com/reprints> **Reprints:** Information about reprints can be found online at:

<http://hyper.ahajournals.org//subscriptions/> **Subscriptions:** Information about subscribing to *Hypertension* is online at: